Abstract
The pharmacokinetics of valganciclovir were studied in 8 infants ranging in age from 4 to 90 days (mean 20 days). We suggest that doses of 15 mg/kg given twice daily may be suitable for neonates and young infants.
MeSH terms
-
Antiviral Agents / therapeutic use*
-
Cytomegalovirus Infections / congenital
-
Cytomegalovirus Infections / drug therapy*
-
Cytomegalovirus Infections / virology
-
DNA, Viral / analysis
-
Female
-
Ganciclovir / analogs & derivatives*
-
Ganciclovir / blood
-
Ganciclovir / therapeutic use
-
Humans
-
Infant
-
Infant, Newborn
-
Male
-
Pilot Projects
-
Valganciclovir
-
Viral Load
Substances
-
Antiviral Agents
-
DNA, Viral
-
Valganciclovir
-
Ganciclovir